- Home
- MGX vs CLPR Comparison
MGX vs CLPR Comparison
Compare MGX & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGX
- CLPR
- Stock Information
- Founded
- MGX 2018
- CLPR 2015
- Country
- MGX United States
- CLPR United States
- Employees
- MGX N/A
- CLPR N/A
- Industry
- MGX
- CLPR Real Estate Investment Trusts
- Sector
- MGX
- CLPR Real Estate
- Exchange
- MGX NYSE
- CLPR Nasdaq
- Market Cap
- MGX 62.1M
- CLPR 57.8M
- IPO Year
- MGX 2024
- CLPR 2017
- Fundamental
- Price
- MGX $2.08
- CLPR $3.78
- Analyst Decision
- MGX Strong Buy
- CLPR
- Analyst Count
- MGX 4
- CLPR 0
- Target Price
- MGX $13.00
- CLPR N/A
- AVG Volume (30 Days)
- MGX 916.2K
- CLPR 93.5K
- Earning Date
- MGX 08-13-2025
- CLPR 07-31-2025
- Dividend Yield
- MGX N/A
- CLPR 10.08%
- EPS Growth
- MGX N/A
- CLPR N/A
- EPS
- MGX N/A
- CLPR N/A
- Revenue
- MGX $45,263,000.00
- CLPR $152,413,000.00
- Revenue This Year
- MGX N/A
- CLPR N/A
- Revenue Next Year
- MGX $11.75
- CLPR N/A
- P/E Ratio
- MGX N/A
- CLPR N/A
- Revenue Growth
- MGX N/A
- CLPR 8.63
- 52 Week Low
- MGX $1.23
- CLPR $3.44
- 52 Week High
- MGX $5.49
- CLPR $7.12
- Technical
- Relative Strength Index (RSI)
- MGX 62.36
- CLPR 52.99
- Support Level
- MGX $2.04
- CLPR $3.55
- Resistance Level
- MGX $2.47
- CLPR $3.69
- Average True Range (ATR)
- MGX 0.18
- CLPR 0.16
- MACD
- MGX 0.07
- CLPR 0.01
- Stochastic Oscillator
- MGX 61.76
- CLPR 77.50
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.